Sinopharm Group Co. Ltd. — Earnings Release 2024

Mar 19, 2025

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

国药集团

SINOPHARM

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE YEAR ENDED 31 DECEMBER 2024

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 19 March 2025 (the "Announcement") in relation to the annual report for the year ended 31 December 2024 of China National Medicines Corporation Ltd. ("SINOPHARM (CNCM LTD)"), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the year ended 31 December 2024 as set out in the Announcement.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."

---

Unit: Yuan
Currency: RMB

PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD)

	Year of 2024	Year of 2023	Changes of this year compared with last year (%)	Year of 2022
Revenue	50,597,449,788.57	49,696,045,528.87	1.81	45,498,583,764.24
Net profit attributable to shareholders of the listed company	2,000,126,943.49	2,145,998,746.54	-6.80	1,964,057,559.33
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	1,996,141,089.85	2,092,945,826.67	-4.63	1,910,981,633.08
Net cash flow arising from operating activities	1,659,119,523.82	2,726,657,097.53	-39.15	2,395,123,454.99
Basic earnings per share (Yuan/Share)	2.6509	2.8443	-6.80	2.6031
Diluted earnings per share (Yuan/Share)	2.6509	2.8443	-6.80	2.6031
Basic earnings per share after deducting non-recurring gains and losses (Yuan/Share)	2.6456	2.7739	-4.63	2.5328
Weighted average return on net assets (%)	12.24	13.68	Decreased by 1.44 percentage points	14.65
Weighted average return on net assets after deducting non-recurring gains and losses (%)	12.21	13.34	Decreased by 1.13 percentage points	14.25

2

---

	At the end of 2024	At the end of 2023	Changes of 2024 year-end over 2023 year-end (%)	At the end of 2022
Net assets attributable to shareholders of the listed company	17,128,090,785.52	15,775,887,678.80	8.57	14,214,807,659.39
Total assets	34,928,279,243.62	32,453,092,592.42	7.63	29,609,041,999.59

INFORMATION ON PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS

The primary reasons for the $39.15\%$ decrease in net cash flow arising from operating activities are attributable to the impact of prevailing market conditions this year, which have resulted in extended payment cycles for certain customers, increased payment pressure on volume-based procurement items, and the consequences of structural adjustments in capital raising.

By order of the Board

Sinopharm Group Co. Ltd.

Zhao Bingxiang

Chairman

Shanghai, the PRC

19 March 2025

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Sun Jinglin; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Hu Ligang, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.